Global Leading Market Research Publisher QYResearch announces the release of its latest report *”Film Coating Agent – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″*. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Film Coating Agent market, including market size, share, demand, industry development status, and forecasts for the next few years.
For pharmaceutical formulators, contract manufacturers, and drug developers, applying a protective polymer layer to solid oral dosage forms (tablets, capsules, pellets, granules) is essential for product performance, patient compliance, and manufacturing efficiency. Uncoated tablets may have bitter taste, poor swallowability, moisture sensitivity (leading to degradation), or cause gastric irritation. Film coating agents directly solve these challenges by providing a thin polymer-based coating sprayed onto dosage forms in pan coaters or fluid bed processors. These coatings offer taste masking, moisture barrier, improved appearance (color, logo), controlled release (enteric protection or sustained release), and easier swallowing. The global market for Film Coating Agent was estimated to be worth USmillionin2025andisprojectedtoreachUSmillionin2025andisprojectedtoreachUS million, growing at a CAGR of % from 2026 to 2032.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/5975095/film-coating-agent
Understanding Film Coating Agents: Polymeric Film Technology
A film coating is a thin polymer-based coating (typically 20-100 μm thickness, 1-5% weight gain) applied to solid pharmaceutical dosage forms. The coating formulation consists of:
- Polymers (film former): Hydroxypropyl methylcellulose (HPMC), polyvinyl alcohol (PVA), polyvinyl alcohol-polyethylene glycol graft copolymer (PVA-PEG), polyvinyl acetate phthalate (PVAP), methacrylic acid copolymers (Eudragit), cellulose acetate phthalate (CAP), ethylcellulose.
- Plasticizers: Polyethylene glycol (PEG), propylene glycol, triethyl citrate, dibutyl sebacate – improve film flexibility, reduce cracking.
- Colorants/opacifiers: Titanium dioxide (white), iron oxides (yellow, red, black), FD&C lakes – product identification, branding.
- Solvents: Water (aqueous coating – preferred, environmental, safer), ethanol, isopropyl alcohol, acetone – organic solvents for water-sensitive drugs.
Application equipment: perforated coating pans, fluid bed coaters (bottom spray, tangential spray).
Critical quality attributes: Coating uniformity (color consistency), film integrity (no cracking), adhesion, dissolution performance, stability.
Market Segmentation by Coating Type (Function)
- Enteric Type (Gastro-resistant, ~35-40% of market value): Coating that remains intact in gastric fluid (pH 1.2-3.0) but dissolves in intestinal fluid (pH 5.5-7.0). Uses pH-sensitive polymers (methacrylic acid copolymers – Eudragit L, S; cellulose acetate phthalate; hydroxypropyl methylcellulose phthalate). Protects acid-labile drugs (omeprazole, lansoprazole – proton pump inhibitors, enzalutamide). Protects gastric mucosa from irritating drugs (aspirin, NSAIDs – naproxen, ibuprofen, diclofenac). Delayed release (targeted intestinal delivery). Enteric coating growth driven by PPI market, NSAID use.
- Gastrolytic (Gastric-soluble, ~40-45% of market value, largest segment): Fast-dissolving coating in stomach (pH 1.2-3.0). Uses water-soluble polymers (HPMC, PVA, HPC). Immediate release formulations (most tablets). Functions: taste masking (bitter APIs – acetaminophen, ibuprofen, antihistamines), moisture barrier, elegance, identification. Gastrolytic dominant due to wide use.
- Slow Release Type (Sustained/extended release, ~15-20% of market value): Coating controls drug release over extended period (8-24 hours). Uses insoluble/erodible polymers (ethylcellulose, Eudragit RS/RL, PVA). Microporous membrane coating, diffusion-controlled release. For once-daily formulations (metformin XL, nifedipine ER, verapamil SR). Reduces dosing frequency, improves compliance. Niche but growing (modified release formulations).
Also functional coatings (taste masking, moisture barrier, compression coating).
Market Segmentation by Application (Dosage Form)
- Tablet (Dominant, ~70-75% of market volume): Most oral solid dosage form. Standard uncoated tablets coated (core tablets coated in pan). Tablet coating largest consumer.
- Pill (Traditional, ~10-15%): Molded pills (herbal, veterinary). Less common.
- Granules (Pellets, ~10-15%): Multiparticulates (pellets in capsules, sachets). Fluid bed coating (Wurster process). Used for modified release (enteric, sustained release pellets). Growing segment (dose dumping prevention, flexible release profiles).
Competitive Landscape and Exclusive Market Observation (2025–2026)
Key Players: Colorcon (US, global leader in pharmaceutical coating systems (~40% market share). Opadry® family (HPMC/PVA based) – complete ready-to-use (mixed with water). Enteric Opadry, Sustained release Surelease® (ethylcellulose). Extensive product portfolio, global technical support), Kerry (Ireland, food/pharma ingredients, coating systems), Alsiano (Denmark, distribution, Omya for coating? not major), Seppic (France, pharmaceutical excipients, film coating polymers (methacrylic copolymers – Eudragit? No, Evonik owns Eudragit). Seppic has separate line), Imerys (minerals, talc used as glidant, not primary coating agent), Silversons (equipment), IFF (ingredients, flavors – used in coating for taste masking). Tianjing ILE (China, local coating manufacturer), Lianyungang Wantai (China), Hunan Gude Pharmaceutical (China), Zhejiang Oulun Coating (China, coating systems), Tianjin Jiahui (China), Liaoning Aoda (China).
Exclusive Industry Insight (H1 2026): Film coating agent market is mature, with Colorcon global leader, regional Chinese players gaining:
- Colorcon dominance: Opadry instant release (HPMC based) – standard for many generic and branded tablets. Turnkey system (requires only water, no additional plasticizers). Provides color matching, technical support, batch-to-batch consistency. Brand loyalty high.
- China local manufacturers: Oulun, Wantai, ILE producing domestic coating systems (lower price, mimic Opadry). Used in Chinese domestic market (VBP products, local pharma). Growing share.
- Regulatory: Film coating agents are excipients (not active ingredients). Pharmaceutical industry uses cGMP grade (USP/NF, PhEur, JP compliant). Not regulated as drugs but must meet compendial standards.
- Trends: Shift to water-based coating (replaces organic solvent – environmental, cost, operator safety). Organic solvents still used for water-sensitive APIs.
User case: Generic Omeprazole (enteric coated tablets). Coating system: Colorcon Opadry Enteric (methacrylic acid copolymer, triethyl citrate, talc, titanium dioxide). Applied in perforated coating pan (20-30% weight gain). Dissolution test: <10% release in acid (2 hours), >80% release in buffer (45 minutes). Protects PPI from gastric degradation.
User case 2: Extended release metformin (500 mg ER). Coating Surelease (Colorcon) ethylcellulose dispersion (pseudo-latex). Plasticized with fractionated coconut oil. Coat applied to metformin granules or pellets, filled into capsules. Diffusion-controlled release over 8-12 hours.
Technical Deep Dive: Enteric Coating Polymers
| Polymer | pH solubility | Application | Trade name |
|---|---|---|---|
| Methacrylic acid copolymer (Type A) | >5.5 | Duodenal release | Eudragit L100 |
| Methacrylic acid copolymer (Type B) | >6.0 | Small intestine, colonic | Eudragit S100 |
| Cellulose acetate phthalate (CAP) | >6.0 | Enteric | Aquacoat CPD |
| HPMC phthalate (HP-55) | >5.5 | Enteric | HP-55 |
Future Outlook (2026–2032): Drivers and Challenges
Growth Drivers:
- Generic drug market growth (enteric, slow release formulations).
- Taste-masking demand (pediatric, geriatric, bitter APIs).
- Modified release formulations (once-daily products, improved compliance).
- Pharmaceutical manufacturing expansion (Asia, India, China, Africa).
Constraints:
- Mature market, low growth: Coating systems widely used, replacement only.
- Alternative dosage forms (orally disintegrating tablets, chewable, liquid) may avoid coating.
Emerging technology: Dry powder coating (no solvents, electrostatic powder coating, experimental). Not commercial.
The market projected moderate growth (2-4% CAGR) – in line with solid oral dosage manufacturing growth. Colorcon retains leadership. China local suppliers capturing domestic share.
Contact Us
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp
